These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2450434)

  • 1. Morphometric differences between cytologically benign and malignant serous effusions.
    Gavin FM; Gray C; Sutton J; Clayden AD; Banks RI; Bird CC
    Acta Cytol; 1988; 32(2):175-82. PubMed ID: 2450434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of computerized morphometric analysis in diagnosis of effusion specimens.
    Arora B; Setia S; Rekhi B
    Diagn Cytopathol; 2006 Oct; 34(10):670-5. PubMed ID: 16955473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cytologic application of carcinoembryonic antigen for the discrimination of malignant from benign serous effusions.
    Kyrkou KA; Iatridis SG; Athanassiadou PP; Athanassiadis PP; Mandragos CE
    Cancer Detect Prev; 1985; 8(1-2):247-54. PubMed ID: 4064045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphometric diagnosis of serous effusions: refinement of differences between benign and malignant cases by use of outlying values and larger sample size.
    Scott N; Sutton J; Gray C
    J Clin Pathol; 1989 Jun; 42(6):607-12. PubMed ID: 2738165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions.
    Sears D; Hajdu SI
    Acta Cytol; 1987; 31(2):85-97. PubMed ID: 3469856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic approach of effusion cytology using computerized image analysis.
    Athanassiadou P; Kavantzas N; Davaris P; Gonidi M; Liossi A; Nakopoulou L; Petrakakou E; Athanassiades P
    J Exp Clin Cancer Res; 2002 Mar; 21(1):49-56. PubMed ID: 12071529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase activity in benign and malignant cytologic fluids.
    Mu XC; Brien TP; Ross JS; Lowry CV; McKenna BJ
    Cancer; 1999 Apr; 87(2):93-9. PubMed ID: 10227600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
    Afify A; Lynne LC; Howell L
    Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive effusion cytology as the initial presentation of malignancy.
    Monte SA; Ehya H; Lang WR
    Acta Cytol; 1987; 31(4):448-52. PubMed ID: 3604540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An immunoperoxidase study of S-100 protein in neoplastic cells in serous effusions. Use as a marker for melanoma.
    Pinto MM
    Acta Cytol; 1986; 30(3):240-4. PubMed ID: 3521174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of pericellular lacunae in cell blocks of effusions.
    Price BA; Ehya H; Lee JH
    Acta Cytol; 1992; 36(3):333-7. PubMed ID: 1580117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contribution of immunocytochemical marking of benign cells to the diagnosis of serous effusions].
    Gaulier A; Cava E; Chosia MC; Pore G; Marsan C
    Ann Pathol; 1986; 6(4-5):323-8. PubMed ID: 3814272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interphase nucleolar organizer regions in the evaluation of serosal cavity effusions.
    Carrillo R; Sneige N; el-Naggar AK
    Acta Cytol; 1994; 38(3):367-72. PubMed ID: 8191825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pericellular lacunae in the diagnosis of metastatic carcinoma in effusions: is this a useful sign?
    Thomson T; Hayes MM
    Diagn Cytopathol; 1996 Sep; 15(3):193-6. PubMed ID: 8955600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
    Illei PB; Ladanyi M; Rusch VW; Zakowski MF
    Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serous effusions in malignant lymphomas: a review.
    Das DK
    Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effusion cytology.
    Ehya H
    Clin Lab Med; 1991 Jun; 11(2):443-67. PubMed ID: 1873966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytologic diagnosis and chromosome analysis: sensitivity, specificity, accuracy and predictive value in malignant and benign pleural effusions.
    Giazza G; Cosimi MF; Lanero M; Rossi GP; Casagranda I
    Pathologica; 1990; 82(1077):33-40. PubMed ID: 2362783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interval between the diagnosis of malignancy and the development of effusions, with reference to the role of cytologic diagnosis.
    van de Molengraft FJ; Vooijs GP
    Acta Cytol; 1988; 32(2):183-7. PubMed ID: 3348059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.